BeiGene’s Post

PD-1 inhibitors are a type of anticancer drug that block the activity of PD-1, a protein on immune cells called T cells. 👉 PD-1 normally acts as an "off switch" to keep T cells from attacking other cells. 👉 However, some cancer cells have large amounts of PD-L1, which helps them hide from an immune attack. 👉 PD-1 inhibitors can block this binding and boost the immune response against cancer cells.

so honored being engaged in the obtaining approval in EU

INBRX-101, currently in the second of three phases of clinical trials, is designed to treat Alpha-1 Antitrypsin Deficiency (AATD)

#GLP1's are everywhere. It feels like everyone and their mother is blissfully and religiously injecting themselves with one of these miracle drugs for diabetes or weight loss. But what is actually happening in the real world? It turns out that people don't stay on these drugs despite the sensational results... Over half of T2DM patients initiating GLP-1 RA were non-adherent and the majority (70.1%) discontinued therapy by 24 months. Reasons for non-adherence and discontinuation merit further research. (Hearn EB, Sherman JJ. Diabetes Spectr. 2021 Jan;34(1):73-75) Can we be curious about why? General injection-site reactions (e.g., erythema, pain, or rash) have been reported with all of the commercially available GLP-1 receptor agonists (i.e., exenatide, lixisenatide, liraglutide, dulaglutide, and semaglutide) All of them (exenatide, lixisenatide, liraglutide, dulaglutide, and semaglutide) cause injection site reactions like erythema , pain, rash . How might adherence change if we treated injection site reactions? Imagine what it might feel like for a patient to receive care these these symptoms that we, on the medical side, tend to label as insignificant. What could a Thimble Recover patch do for medication adherence and for the patient experience? Would you want your injections to come with solutions to alleviate the discomfort? #stickwithcompassion

#NEW from #AAIC2023 | The Phase III #LUCIDITYtrial: a #tau aggregation inhibitor in patients with #Alzheimersdisease 🎥 🧠 Sonya Miller, MBBS, FFARCS, FANZCA, TauRx, discusses the recent double-blind, randomized, controlled Phase III LUCIDITY trial (NCT03446001) of the oral drug #hydromethylthioninemesylate (HMTM; aka TRx0237) This global #clinicaltrial enrolled patients from across the #Alzheimer’s disease (AD) spectrum, assessing changes in Alzheimer’s Disease Assessment Scale–Cognitive (ADAS-Cog) and activities of daily living (ADL) scores as the primary endpoints ⭐ Data from the trial has demonstrated a sustained improvement in #cognition in the MCI group and a reduction in the expected #cognitivedecline in the mild to moderate AD group, after 12 months of drug treatment ⭐ This has been further supported by a 93% reduction in change in neurofilament light chain (NfL) from baseline to 12 months, relative to controls ⭐ The group are currently beginning discussions with regulators in the UK, to bring this drug to patients with AD and #frontotemporaldementia Find out more 👉 https://lnkd.in/euBAe9PR #Dementia

Read this to learn more about how ambulatory ECG helps Afib patients start on critical medications and supports monitoring of responses to therapy such as antiarrhythmic drug therapy. #DCARInsights #GEHealthcare #ECG

In an interview with The Clinical Trial Vanguard’s Moe Alsumidaie, Elysium Therapeutics, Inc. CEO Greg Sturmer discusses O2P, a groundbreaking path to #painrelief that’s designed to help reduce the risk of opioid misuse. #opioidoverdose #opioidepidemic #painmedication #opioidmisuse #elysiumtherapeutics #hydrocodone https://lnkd.in/eUnapmfJ

Very exciting update on ATAI Life Sciences AG's and Beckley Psytech's Phase 1/2a trial of ELE-101 for Major Depressive Disorder (MDD). ELE-101 is a patent-protected, intravenous formulation of psilocin, which is the active moiety in the body when psilocybin is administered orally. As such, I view ELE-101 as a relatively de-risked asset for its stage of development, as it leverages the robust proof-of-concept data that has been established with psilocybin across multiple trials. Especially, it has the potential to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter (!) treatment paradigm of less than 2 hours. So much larger TAM/business upside. #psychedelics #investing #future

Lung SAEC services. Evaluate new drugs for idiopathic pulmonary fibrosis. Assess toxicity of your new drug with our unique lung SAEC assay service Speak to our lung experts to design your study. https://t.ly/My_dH #FMTassay #chronicpulmonaryfibrosis #SAECModel #lungfibrosis #lungdisease

Lung SAEC services. Evaluate new drugs for idiopathic pulmonary fibrosis. Assess toxicity of your new drug with our unique lung SAEC assay service Speak to our lung experts to design your study. https://t.ly/My_dH #FMTassay #chronicpulmonaryfibrosis #SAECModel #lungfibrosis #lungdisease